Fairvalue-Calculator Fairvalue-Calculator
EN DE

Genomics BioSci & Tech. Co (4195) Fair Value & Analysis

Healthcare · TW · Market cap 2.4B TWD

Price15.70 TWD
Fair Value28.71 TWD
Upside+82.9%
Quality88/100
Evidence: Low Range 21.53 TWD – 35.88 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Genomics BioSci & Tech. Co (4195) currently trades at 15.70 TWD, while our model-based Fair Value estimate is 28.71 TWD — implying the stock looks roughly 82.9% undervalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Genomics BioSci & Tech. Co.,Ltd. operates as a genomic company in Taiwan. The company offers sequencing, synthesis, genomic, proteomic, and agency and sales services; clinical testing services, such as reproductive health and cancer testing services; and contract development and manufacturing services. The company was founded in 2001 and is based in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Genomics BioSci & Tech. Co (4195) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 28.71 TWD versus a price of 15.70 TWD — about +83% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 4195?
Our 21-model fair value for Genomics BioSci & Tech. Co is 28.71 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 15.70 TWD.
What is the quality score of 4195?
Genomics BioSci & Tech. Co has a Quality Score of 88/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.